Loading
A phase 1/2 trial of Sunvozertinib, Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Dizal Pharmaceuticals, now recruiting.
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) is a phase 1/2 interventional study registered as NCT07079475 by Dizal Pharmaceuticals, with 220 participants planned, started 2025-07-30 and due to reach its primary completion in 2028-06. Interventions recorded: DZD6008, Sunvozertinib, Osimertinib. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Sunvozertinib, Dizal Pharmaceutical, EGFR-mutated non-small-cell lung cancer.
Shares Sunvozertinib, Dizal Pharmaceutical, Small-cell lung cancer, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/